NLRP3 and hyperuricemia: To verify whether NLRP3 activation could be detected in MS patients with different disease phenotypes, and to determine if hyperuricemia drives NLRP3 activation in MS, we analyzed uric acid serum concentration and NLRP3 inflammasome activation in MS patients affected by active MS or with a clinically quiescent disease.